Point72 Europe (London) LLP Aldeyra Therapeutics, Inc. Transaction History
Point72 Europe (London) LLP
- $1.97 Billion
- Q3 2025
A detailed history of Point72 Europe (London) LLP transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Point72 Europe (London) LLP holds 915 shares of ALDX stock, worth $4,639. This represents 0.0% of its overall portfolio holdings.
Number of Shares
915Holding current value
$4,639% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ALDX
# of Institutions
145Shares Held
39.9MCall Options Held
344KPut Options Held
71.7K-
Knoll Capital Management, LLC Miami, FL5.48MShares$27.8 Million15.99% of portfolio
-
Perceptive Advisors LLC New York, NY5.22MShares$26.5 Million0.06% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$18.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.59MShares$18.2 Million0.0% of portfolio
-
Ardsley Advisory Partners LP Stamford, CT1.9MShares$9.63 Million1.4% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $296M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...